{"altmetric_id":6496878,"counts":{"readers":{"mendeley":67,"citeulike":0,"connotea":0},"total":{"posts_count":2},"news":{"unique_users_count":2,"unique_users":["the_conversation","newsmax_com"],"posts_count":2}},"citation":{"authors":["S.J. Hotte","F. Saad"],"first_seen_on":"2016-04-06T14:43:55+00:00","issns":[],"issue":"Suppl 2","journal":"Current Oncology","last_mentioned_on":1464977100,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2935714\/"],"pmid":"20882137","pubdate":"2010-09-01T00:00:00+00:00","publisher":"Multimed Inc.","startpage":"S72","title":"Current management of castrate-resistant prostate cancer.","type":"article","volume":"17","mendeley_url":"http:\/\/www.mendeley.com\/research\/current-management-castrateresistant-prostate-cancer-4"},"altmetric_score":{"score":16,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":16},"context_for_score":null},"demographics":{"users":{"mendeley":{"by_status":{"Professor > Associate Professor":3,"Researcher":6,"Student  > Doctoral Student":4,"Student  > Ph. D. Student":16,"Student  > Postgraduate":4,"Student  > Master":16,"Other":5,"Student  > Bachelor":11,"Lecturer":2},"by_discipline":{"Medicine and Dentistry":18,"Physics and Astronomy":1,"Mathematics":1,"Unspecified":1,"Environmental Science":1,"Pharmacology, Toxicology and Pharmaceutical Science":2,"Engineering":1,"Chemistry":3,"Neuroscience":2,"Economics, Econometrics and Finance":1,"Agricultural and Biological Sciences":21,"Computer Science":1,"Business, Management and Accounting":1,"Nursing and Health Professions":1,"Biochemistry, Genetics and Molecular Biology":12}}},"geo":{"mendeley":{"CA":3,"US":2,"GB":1,"ZA":1,"PT":1}}},"posts":{"news":[{"title":"The high cost of publicly funded cancer drugs","url":"http:\/\/ct.moreover.com\/?a=26077852143&p=1pl&v=1&x=1MNNjVFarICLlXg1lkoD6A","license":"public","citation_ids":[1116937,6496878],"posted_on":"2016-04-06T10:59:11+00:00","summary":"Patients with prostate cancer in England and Wales will now have early access to abiraterone, a drug which can delay the need for chemotherapy.","author":{"name":"The Conversation","url":"http:\/\/theconversation.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/071\/normal\/the_conversation.png?1369846953"}},{"title":"Castration-Resistant Prostate Cancer Definition: What Is It?","url":"http:\/\/ct.moreover.com\/?a=26766501411&p=1pl&v=1&x=6xQJtlWYY_2XeagC9uI2FQ","license":"public","citation_ids":[6496878],"posted_on":"2016-06-03T18:05:00+00:00","summary":"Castration-resistant prostate cancer fits that definition when the level of prostate-specific antigen (PSA) keeps rising or new symptoms appear even after the cancer has been treated with radiation or surgery.","author":{"name":"newsmax.com","url":"http:\/\/www.newsmax.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/354\/normal\/Screen_Shot_2015-04-07_at_17.01.46.png?1428422529"}}]}}